Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Mariel Elena Boyd"'
Autor:
Eliezer M. Van Allen, Ilana Rebecca Garcia-Grossman, Azeez Farooki, Irina Ostrovnaya, Matthew I. Milowsky, Brendan Reardon, Asia S. McCoy, Andrew J. Roth, Aravind Bhayankara, Mariel Elena Boyd, Victor McPherson, David B. Solit, Michael F. Berger, Dean F. Bajorin, Philip H. Kim, Hikmat Al-Ahmadie, Gopa Iyer, Jonathan E. Rosenberg, Ashley Marie Regazzi, Sasinya N. Scott
Publikováno v:
Cancer
Background The phosphatidyl 3-inositol kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway frequently is activated in patients with urothelial carcinoma (UC). In the current study, the authors performed a phase 2 study evaluating the eff
Autor:
David M. Hyman, Nancy Bouvier, Emmet Jordan, Irina Ostrovnaya, Mariel Elena Boyd, Eugene K. Cha, Bernard H. Bochner, David B. Solit, Michael F. Berger, Min Yuen Teo, Nitin Roper, Dean F. Bajorin, Joaquim Bellmunt, Stephanie A. Mullane, Richard Martin Bambury, Gopakumar Iyer, Emily C. Zabor, Maria E. Arcila, Hikmat Al-Ahmadie, Jonathan E. Rosenberg
Publikováno v:
Clinical Cancer Research. 23:3610-3618
Purpose: Platinum-based chemotherapy remains the standard treatment for advanced urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in DNA damage response and repair (DDR) genes are associated with improved sensitivi
Autor:
Nicholas R Brown, Johan Adami, Amy P. Abernethy, Irene Kaganman, Sean Khozin, Rebecca A. Miksad, Anala Gossai, Deborah Kuk, Aracelis Z. Torres, Richard Pazdur, Jizu Zhi, Jillian Motyl Rockland, Mariel Elena Boyd
Publikováno v:
Cancer
Background Despite the rapid adoption of immunotherapies in advanced non–small cell lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw) performance. Methods This retrospective, observational, multicenter analysis used the Fl
Autor:
Bernard H. Bochner, Richard Martin Bambury, Maria E. Arcila, Irina Ostrovnaya, Dean F. Bajorin, Hikmat Al-Ahmadie, Michael F. Berger, Emily C. Zabor, David B. Solit, Mariel Elena Boyd, M Y Teo, Emmet Jordan, Jonathan E. Rosenberg, Nancy Bouvier, Nitin Roper, David M. Hyman, Gopakumar Iyer, Joaquim Bellmunt, Stephanie A. Mullane, Eugene K. Cha
Publikováno v:
Urologic oncology. 36(7)
Purpose Platinum-based chemotherapy remains the standard treatment for advanced urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in DNA damage response and repair (DDR) genes are associated with improved sensitivit
Autor:
Andreas Meier, Bernard H. Bochner, Maha Shady, Hebert Alberto Vargas, Arjun Vasant Balar, Guido Dalbagni, Matthew I. Milowsky, Gopa Iyer, S. Machele Donat, Jonathan E. Rosenberg, Ashley Marie Regazzi, William C. Huang, Caitlin Bourque, Daniela Delbeau, H. Al-Ahmadie, H Herr, David B. Solit, Tracy L. Rose, Michael F. Berger, Irina Ostrovnaya, Helen Won, William Y. Kim, Jamie Riches, Maria E. Arcila, Brooke Elizabeth Kania, Mariel Elena Boyd, Samir S. Taneja, Asia S. McCoy, Dean F. Bajorin, Michael Woods, Catharine Kline Cipolla
Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin-based regimens have yielded favorable outcomes compared with standard-dose ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84c4723b748b51520edab6a7369bb11d
https://europepmc.org/articles/PMC6049398/
https://europepmc.org/articles/PMC6049398/
Autor:
Bulent Arman Aksoy, Tavi Nathanson, Meredith Maisie Moran, Eliza Chang, Matthew D. Hellmann, Harlan Robins, Arun Ahuja, Taha Merghoub, Alexandra Snyder, Samuel Funt, Marissa Vignali, Elaine R. Mardis, Mariel Elena Boyd, Erik Yusko, Jacqueline Buros Novik, Hikmat Al-Ahmadie, Gopa Iyer, Jonathan E. Rosenberg, Dean F. Bajorin, Sharon Benzeno, Jeff Hammerbacher
Background:Inhibition of programmed death-ligand one (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial cancers, including complete remissions in patients with chemotherapy refractory disease. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9423b7608d1bf671571ab0e04e896f22
Autor:
Harlan Robins, Bulent Arman Aksoy, Tavi Nathanson, Hikmat Al-Ahmadie, Elaine R. Mardis, Meredith Maisie Moran, Sharon Benzeno, Taha Merghoub, Jacqueline Buros Novik, Eliza Chang, Matthew D. Hellmann, Arun Ahuja, Mariel Elena Boyd, Gopa Iyer, Marissa Vignali, Samuel Funt, Jonathan E. Rosenberg, Alexandra Snyder, Dean F. Bajorin, Erik Yusko, Jeff Hammerbacher
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 14, Iss 5, p e1002309 (2017)
PLoS Medicine, Vol 14, Iss 5, p e1002309 (2017)
Background Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial cancers, including complete remissions in patients with chemotherapy refractory disease. Alt
Autor:
Hikmat Al-Ahmadie, Ashley Marie Regazzi, Dean F. Bajorin, Bishoy Faltas, Catharine Kline Cipolla, Min Yuen Teo, Samuel Funt, Chung-Han Lee, Mariel Elena Boyd, Gopa Iyer, Jonathan E. Rosenberg, Alexander Solovyov, Benjamin Greenbaum
Publikováno v:
Journal of Clinical Oncology. 37:443-443
443 Background: Defining the role of MIBC molecular subtypes and immune expression in determining clinical outcomes is an area of active investigation. However, changes in these transcriptomic profiles pre- and post-NAC have not been well characteriz
Autor:
Martin H. Voss, Wassim Abida, Matthew I. Milowsky, Andrea B. Apolo, Irina Ostrovnaya, Mariel Elena Boyd, Jonathan E. Rosenberg, Asia S. McCoy, Ashley Marie Regazzi, Scott R. Gerst, Dean F. Bajorin
Publikováno v:
Bladder Cancer
Background: Cisplatin-based combination chemotherapy is standard first-line treatment for patients with advanced urothelial carcinoma (UC). Molecular profiling studies reveal that the PI3K/AKT/mTOR pathway is altered in a significant percentage of UC
Autor:
Gopa Iyer, Jonathan E. Rosenberg, Hikmat Al-Ahmadie, Maria E. Arcila, Mariel Elena Boyd, Donavan T. Cheng, Dean F. Bajorin, David M. Hyman, Eugene K. Cha, Aditya Bagrodia, Richard Martin Bambury, Marc Ladanyi, Agnes Viale, Berger Michael, Ahmet Zehir, David B. Solit, Bernard H. Bochner
Publikováno v:
Journal of Urology. 193
with the BSCC group, while the incidence of lymph node metastasis in the BSCC group was significantly higher than that in the UC group. Of the 12 EMT markers, N-cadherin expression in the UC group was significantly greater than that in the BSCC group